Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

NCT02173171 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02173171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02173171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
April 27, 2010
Completion date
September 23, 2021
Enrollment
185 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

any tumor type eligible for treatment with talimogene laherparepvec in amgen or biovex-sponsored clinical trial